GenSight Biologics Reports Sustained Quality of Life Improvements at Week 72 of Phase III REVERSE Clinical Trial of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON)

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported that Week 72 analyses of the data from its Phase III REVERSE clinical trial revealed a sustained improvement in composite scores and selected sub-scores of a questionnaire used to measure pati

Full Story →